Navigation Links
Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I
Date:10/2/2008

PARIS, October 2 /PRNewswire/ -- Pharmaleads has obtained from the French Medicine Agency (AFSSAPS) the authorization to perform a single ascending dose Phase I study with PL37, its lead compound for oral treatment of neuropathic pain.

Neuropathic pain is a major chronic pain condition, with an estimated prevalence in the world's population of up to 6%, according to the most recent surveys, with many causes such as shingles, herpes, diabetes, antiviral or antitumor chemotherapy surgery, or low back disorders. Neuropathic pain does not respond well to usual painkillers. Worldwide market for neuropathic pain is estimated to reach 5 billion USD by 2010.

This compound originates from the work of Pharmaleads' chief scientists, Professors Bernard P. Roques and Marie-Claude Fournie-Zaluski, and is a dual inhibitor of both enzymes responsible for the rapid degradation of enkephalins, the endogenous opiates. It therefore elicits an analgesic effect wherever enkephalins are produced as a response to a painful stimulus, and maintains a high level of these natural analgesic substances by preventing their rapid degradation.

According to Thierry Bourbie, Chairman and CEO of Pharmaleads, "PL37 is Pharmaleads' first compound to enter clinical development and the first representative of a totally new class of painkillers, hence confirming the validity of our science and chemistry, as well as our capabilities as a drug development company. Neuropathic pain remains poorly treated and there is an urgent need to develop and bring to patients and doctors a specific oral treatment that would be really active and well tolerated. This looks very promising."

Bernard P. Roques, Vice-President and CSO of Pharmaleads explains: "The inhibition of both enzymes, responsible for the inactivation, in the body, of naturally present opiates, enhances their analgesic properties. PL37 physiological action in all areas where pain is present leads to very promising properties in peripheral neuropathic disorders."

Michel Wurm, M.D., Director of Corporate Development at Pharmaleads stated: "Pre-clinical studies have demonstrated the safety and efficacy of PL37 across all known models for neuropathic pain. The bioavailability of this oral compound is remarkable, as is its safety margin. We hope to complete Phase I in less than a year, including early pharmacodynamic testing in healthy volunteers."

The pre-clinical program was financed with the support of OSEO, the French Public Research Financing Institution.

About Pharmaleads:

Pharmaleads is a pharmaceutical company focusing on research and early development of small molecules. Headquartered in Paris, France, Pharmaleads was founded in 2001 by Professors Bernard P. Roques, pharmacist and PhD in chemistry, Member of the French Academy of Sciences, and Marie-Claude Fournie-Zaluski, PhD in chemistry, both of them inventors of drugs (2 on the market). They were joined in 2004 by Thierry Bourbie, alumnus from Polytechnique and Mines, PhD from Stanford, (former Deputy General Manager, Suez Group) and Jean-Pierre Rogala, PhD from Agro, MBA from MIT (IBM, Suez Group). They were able to bring in their first rank international business expertise to fully unleash the world-class capabilities of the company in pharmacology and medicinal chemistry. In 2006, Michel Wurm, M.D. joined and added his extensive experience in drug and business development.

For further information, please contact:

PHARMALEADS YUCATAN

Michel Wurm, MD, Annie-Florence Loyer

Director, Corporate Development +33-1-53-63-27-29

+33-1-440-670-04 afloyer@yucatan.tm.fr

michel.wurm@pharmaleads.com

http://www.pharmaleads.com


'/>"/>
SOURCE Pharmaleads
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
4. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
5. InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
8. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
9. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
10. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... PUNE, India , January 24, 2017 /PRNewswire/ ... Market Research, titled, "Cold Chain Logistics Market by Application ... Frozen Dessert, Meat, Fish & Sea Food, Drugs & ... Forecasts, 2014-2022," projects that the global cold chain logistics ... growing at a CAGR of 16% (2016 to 2022). ...
(Date:1/24/2017)... , Jan. 24, 2017 Regeneron Pharmaceuticals, Inc. ... Public today recognized 40 finalists in the Regeneron Science ... and math competition for high school seniors. Finalists were ... of their research projects. The finalists will ... from March 9-15 to undergo a rigorous judging process ...
(Date:1/24/2017)... 24, 2017 Research and Markets has announced ... Trends - Product, Material - Forecast to 2025" report to ... ... a CAGR of around 5.4% over the next decade to reach ... trends that the market is witnessing include 3D medical printing is ...
Breaking Medicine Technology:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... This Saturday, ... & magic, plus a very special performance by Alabama Symphony Orchestra musicians Yifan Zhou, ... their specialties, such as dim sum, and exhibitors offer a look at Chinese games, ...
(Date:1/24/2017)... ... 2017 , ... Inspiration, Community & Mentorship – Top Students ... Fordham Institute’s High Stakes for High Achievers offer recommendations for how ... high-achieving students as a subgroup and reporting their results separately. Top students and ...
(Date:1/24/2017)... Pass, OR (PRWEB) , ... January 24, 2017 ... ... Gerald H. Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost ... of Water, Global Climate Change and Your Health on Voice America, once again ...
(Date:1/24/2017)... Scottsdale, AZ (PRWEB) , ... January 24, 2017 , ... ... than 30 lives in the last month. Yellow fever is primarily spread through contact ... the health community’s focus on how to prevent its spread. , According to multiple ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... to topics like finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common ... Publishing authors, Dr. Judith Coats and Dr. David Coats. In September of 1983, ...
Breaking Medicine News(10 mins):